GENETICS OF ATOPIC DERMATITIS
GENETICS OF ATOPIC DERMATITIS
批准号:
7604695
负责人:
ROBERT A WOOD
金额:
$0.05万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-12-01 至 2007-09-16
关键词:
Adverse reactionsAffectAge-YearsAtopic DermatitisBiologicalBioterrorismCessation of lifeChildComputer Retrieval of Information on Scientific Projects DatabaseConditionCoupledDiseaseEczema VaccinatumFundingGeneral PopulationGeneticGrantIndividualInstitutionLifeMeasuresPopulationPrevalencePublic HealthRateRecording of previous eventsResearchResearch PersonnelResourcesRiskSeptic ShockSkinSmallpoxSmallpox VaccineSmallpox VirusesSourceSymptomsTodayUnited States National Institutes of HealthVaccinationVaccinesVacciniaVaccinia virusVirusmortalityprophylacticskin disordervaccine-induced immunityyoung adult
中文摘要
点击翻译按钮获取中文摘要
英文摘要
This subproject is one of many research subprojects utilizing the
resources provided by a Center grant funded by NIH/NCRR. The subproject and
investigator (PI) may have received primary funding from another NIH source,
and thus could be represented in other CRISP entries. The institution listed is
for the Center, which is not necessarily the institution for the investigator.
Today's increased threat of bioterrorism has caused renewed concern about smallpox. Large-scale vaccination or re-vaccination of the civilian population as a prophylactic measure against possible bioterrorist attack is currently an important public health concern. However, the smallpox vaccine is not without risk. The live-virus vaccine, composed of the smallpox-related virus vaccinia, has the highest rate of adverse reactions among all vaccines. Most serious is eczema vaccinatum (EV), a potentially life-threatening condition in which the virus spreads unchecked throughout the skin. When untreated, EV causes severe systemic symptoms resembling septic shock leading to death in 40% of cases. Mortality rates are higher in children under 2 years of age. Individuals particularly at risk include those with a history of atopic dermatitis (AD). AD is most common in children and young adults and the global prevalence of AD and other atopic disorders has been on the rise. Recent studies suggest that more than 10% of children are affected by AD. The increased threat of bioterrorism and the possibility of the smallpox virus for use as a biological weapon, coupled with the lack of natural or vaccine-induced immunity among the general population, have understandably led to discussion about reinstating routine smallpox vaccination. It cannot be predicted who will get EV, although, since 40% of the U.S. population is immunologically na¿ve to vaccinia and immuno-compromising factors (skin diseases such as AD) are more prevalent today than in the past, the rate of EV would most likely be higher than during the era when smallpox vaccination was routine. These risks must be carefully considered in any public health discussion regarding smallpox vaccination.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Treatment of Peanut Allergy with Intradermal Administration of ASP0892 (ARA-LAMP-vax): A Randomized, Double-Blind, Placebo-Controlled, Phase I/II Study
-
批准号:10363633
-
项目类别:
-
资助金额:$675.4万
-
财政年份:2017
-
负责人:ROBERT A WOOD
-
依托单位:
Clinical Research Unit: Johns Hopkins University
-
批准号:9307452
-
项目类别:
-
资助金额:$23.5万
-
财政年份:2017
-
负责人:ROBERT A WOOD
-
依托单位:
Leadership Center Administration
-
批准号:10363632
-
项目类别:
-
资助金额:$272.01万
-
财政年份:2017
-
负责人:ROBERT A WOOD
-
依托单位:
Treatment of Peanut Allergy with Intradermal Administration of ASP0892 (ARA-LAMP-vax): A Randomized, Double-Blind, Placebo-Controlled, Phase I/II Study
-
批准号:10664077
-
项目类别:
-
资助金额:$299.87万
-
财政年份:2017
-
负责人:ROBERT A WOOD
-
依托单位:
Treatment of Peanut Allergy with Intradermal Administration of ASP0892 (ARA-LAMP-vax): A Randomized, Double-Blind, Placebo-Controlled, Phase I/II Study
-
批准号:10581630
-
项目类别:
-
资助金额:$744.0万
-
财政年份:2017
-
负责人:ROBERT A WOOD
-
依托单位:
Treatment of Peanut Allergy with Intradermal Administration of ASP0892 (ARA-LAMP-vax): A Randomized, Double-Blind, Placebo-Controlled, Phase I/II Study
-
批准号:10398332
-
项目类别:
-
资助金额:$577.06万
-
财政年份:2017
-
负责人:ROBERT A WOOD
-
依托单位:
Leadership Center Administration
-
批准号:10581629
-
项目类别:
-
资助金额:$87.42万
-
财政年份:2017
-
负责人:ROBERT A WOOD
-
依托单位:
Clinical Research Unit: Johns Hopkins University
-
批准号:10378487
-
项目类别:
-
资助金额:$23.5万
-
财政年份:2017
-
负责人:ROBERT A WOOD
-
依托单位:
Clinical Research Unit: Johns Hopkins University
-
批准号:10580033
-
项目类别:
-
资助金额:$23.5万
-
财政年份:2017
-
负责人:ROBERT A WOOD
-
依托单位:
Immunotherapeutic Modulation of Peanut Allergy
-
批准号:9305647
-
项目类别:
-
资助金额:$134.48万
-
财政年份:2016
-
负责人:ROBERT A WOOD
-
依托单位:
Immunotherapeutic Modulation of Peanut Allergy
-
批准号:8022445
-
项目类别:
-
资助金额:$177.81万
-
财政年份:2010
-
负责人:ROBERT A WOOD
-
依托单位:
Core--Subject Characterization and Recruitment
-
批准号:7150233
-
项目类别:
-
资助金额:$18.53万
-
财政年份:2006
-
负责人:ROBERT A WOOD
-
依托单位:
URBAN ENVIRONMENT AND CHILDHOOD ASTHMA
-
批准号:7604673
-
项目类别:
-
资助金额:$0.39万
-
财政年份:2006
-
负责人:ROBERT A WOOD
-
依托单位:
ORAL IMMUNOTHERAPY FOR COW'S MILK ALLERGY
-
批准号:7604688
-
项目类别:
-
资助金额:$0.17万
-
财政年份:2006
-
负责人:ROBERT A WOOD
-
依托单位:
AN OBSERVATIONAL STUDY OF FOOD ALLERGY
-
批准号:7604690
-
项目类别:
-
资助金额:$0.11万
-
财政年份:2006
-
负责人:ROBERT A WOOD
-
依托单位:
ADVN BIOMARKER REGISTRY STUDY
-
批准号:7604694
-
项目类别:
-
资助金额:$0.05万
-
财政年份:2006
-
负责人:ROBERT A WOOD
-
依托单位:
FOOD ALLERGY IN ADULTS AND ADOLESCENTS
-
批准号:7604689
-
项目类别:
-
资助金额:$0.19万
-
财政年份:2006
-
负责人:ROBERT A WOOD
-
依托单位:
TREE NUT ALLERGY
-
批准号:7378868
-
项目类别:
-
资助金额:$0.05万
-
财政年份:2005
-
负责人:ROBERT A WOOD
-
依托单位:
PEANUT ALLERGY
-
批准号:7200755
-
项目类别:
-
资助金额:$0.07万
-
财政年份:2005
-
负责人:ROBERT A WOOD
-
依托单位:
TREE NUT ALLERGY
-
批准号:7200795
-
项目类别:
-
资助金额:$0.52万
-
财政年份:2005
-
负责人:ROBERT A WOOD
-
依托单位:
海外基金